Publications by authors named "Nadia Tenenbaum"

Claim this Profile
S
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Xavier Montalban, Patrick Vermersch, Douglas L Arnold, Amit Bar-Or, Bruce A C Cree, Nadia Tenenbaum

Lancet Neurol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum tau protein elevation in migraine: a cross-sectional case-control study.
Lucas Hendrik Overeem, Bianca Raffaelli, Robert Fleischmann, Marie Süße, Antje Vogelgesang, Nadia Tenenbaum

J Headache Pain· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study.
Michel Dominique Ferrari, Uwe Reuter, Peter J Goadsby, Gabriel Paiva da Silva Lima, Subhayan Mondal, Nadia Tenenbaum

J Neurol Neurosurg Psychiatry· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
Richard B Lipton, David W Dodick, David Kudrow, Uwe Reuter, Nadia Tenenbaum

Cephalalgia· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.
Shuu-Jiun Wang, Artemio A Roxas, Bibiana Saravia, Byung-Kun Kim, Debashish Chowdhury, Nadia Tenenbaum

Cephalalgia· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study.
Peter J Goadsby, Uwe Reuter, Michel Lanteri-Minet, Gabriel Paiva da Silva Lima, Peggy Hours-Zesiger, Nadia Tenenbaum

Neurology· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes.
Samuel F Hunter, Florian P Thomas, Mark Cascione, Ian M Williams, Xiangyi Meng, Nadia Tenenbaum

Mult Scler Relat Disord· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Bruce A C Cree, Myla D Goldman, John R Corboy, Barry A Singer, Edward J Fox, Nadia Tenenbaum

JAMA Neurol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results.
Jeffrey A Cohen, Nadia Tenenbaum, Alit Bhatt, Ying Zhang, Ludwig Kappos

Ther Adv Neurol Disord· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.
Mark Cascione, Nadia Tenenbaum, Jeanette Wendt, Xiangyi Meng, Lesley Schofield

Mult Scler Relat Disord· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase IV study of retention on fingolimod injectable multiple sclerosis therapies: a randomized clinical trial.
Bruce A C Cree, Douglas L Arnold, Mark Cascione, Edward J Fox, Ian M Williams, Nadia Tenenbaum

Ther Adv Neurol Disord· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Jonathan Calkwood, Bruce Cree, Heidi Crayton, Daniel Kantor, Brian Steingo, Nadia Tenenbaum

BMC Neurol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
Angel R Chinea Martinez, Jorge Correale, Patricia K Coyle, Xiangyi Meng, Nadia Tenenbaum

Adv Ther· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.
Murat Emre, Werner Poewe, Peter Paul De Deyn, Paolo Barone, Jaime Kulisevsky, Nadia Tenenbaum

Clin Neuropharmacol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis